CONFERENCE DAY TWO - WEDNESDAY FEBRUARY, 12

Breakfast Briefing Workshop

8:00 am Workshop Chair’s Opening Remarks

Synopsis

Join this exclusive workshop to engage in mixed-insight discussions with fellow DTx leaders & stakeholders to learn from your peers, build industry alignment, and collaborate to bring commercial viability to the DTx sector

8:10 am Topic 1:Overcoming Limiting Factors in Digital Therapeutic Commercialization

Synopsis

  • Discussing the primary limiting factors hindering commercialization, including reimbursement challenges and low patient adoption
  • Learn how to address these obstacles early in development to prevent delays and misalignment with reimbursement strategies
  • Exploring the allocation of capital effectively at each critical stage of DTx company growth
  • Discover common pitfalls that impact commercialization strategies and how to avoid them

8:50 am Topic 1 Discussion: Engage in moderated Q&A & round-table discussions into commercialization bottlenecks

9:05 am Topic 2: Operational Learnings from DTx Rollout: Stories from the Front Lines

  • Raj Amin Cofounder & Chief Executive Officer, Arcade Therapeutics
  • Samuel Nordberg Chair of Psychiatry and Behavioral Health, Reliant Medical Group

Synopsis

  • Gain first-hand insights from industry stakeholders on the challenges and successes of integrating digital therapeutics into healthcare systems
  • Discover key factors influencing patient experiences and adoption rates to refine your DTx implementation strategy
  • Learn how to identify and capitalize on unexpected sources of value in DTx deployments to maximize impact and patient outcomes

9:45 am Topic 2 Discussion: Engage in moderated Q&A & round-table discussions exploring operational & rollout optimization to get your products into patient hands efficiently

10:00 am Break & Morning Coffee

10:25 am Chair’s Opening Remarks & Start of Day Two

Improving Product Design to Increase Adoption & Engagement

10:30 am Case Study: Adopting Assistive Onboarding to Increase Product Uptake Out of the Clinic

Synopsis

  • Examine a case study on how in-person assistive onboarding can improve patient engagement and product uptake
  • Create onboarding experiences that encourage user engagement, sustain adoption, and reduce drop-off rates
  • Gain actionable insights into improving physician education and awareness of DTx products to increase adoption rates of patients

11:00 am Roundtable Activity: Designing a Novel Digital Therapeutic Product

Synopsis

Engage with your peers across the DTx space to partake in a thought-experiment roundtable session to quickly design a product concept, research plan, and commercialization roadmap for a potential new DTx product. Foster new connections with other industry leaders, test your Digital Health initiative, and learn from the professional experience of others in this interactive session

11:45 am Morning Break & Networking

Synopsis

Take advantage of this cross-functional event to have a go at our Speed Networking! In quick 5min sessions rotate around the room to chat and network with experts and key opinion leaders you may not have crossed paths with before.

12:30 pm Balancing AI Chatbots & Human Intervention to Maximize Health Outcomes

Synopsis

  • Explore the complementary roles of human-led care and AI-driven chatbots in optimizing patient support
  • Assess the current capabilities of AI chatbots and identify when human intervention is still necessary
  • Understand how AI tools can enhance operational efficiencies and improve health outcomes. Implications of generative AI

1:00 pm Lunch & Networking

Assessing Current & Future Regulations for DTx’s to Guide Commercialization Strategy

2:00 pm Panel Discussion Integrating Forward Development Plans (PCCP) into FDA Approval to Facilitate Growth & Iterative Design

Synopsis

  • What does the “Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/ Machine Learning (AI/ML)-Enabled Device Software Functions” Guidance mean?
  • Forward planning your product development to facilitate improvements and content upgrades during the approval and postapproval period
  • Incorporating long-term growth into FDA discussions and applications paving the way for future iterations of your product without requiring additional approvals

2:45 pm Roundtable Discussion: Achieving Broader Adoption of DTx Products Through Political and Lobbying Efforts

Synopsis

  • How can industry collaboration to influence future regulatory frameworks for DTx products
  • Discussing potential policies that provide more sustainable commercial options for DTx companies and better health outcomes for patients
  • How should diverse digital therapeutic products across different commercialization & regulatory pathways be treated differently by regulatory and legal frameworks?

3:30 pm Fireside Chat: Investments, Consolidations, & M&A: Understanding the Post-Covid Digital Therapeutic Landscape

  • Jeff Weness Head of Digital Opportunities and Investments, Otsuka Precision Health, Inc

Synopsis

  • Discussing the evolution of the digital therapeutics market considering major commercialization success stories and failures
  • Does consolidating digital therapeutic backends provide an increase in operational and profit viability?
  • How can the DTx market correctly capitalise off recent regulatory and commercial precedent?

4:15 pm Chair’s Closing Remarks & End of the Advancing Digital Therapeutics Summit